Xi’an DELI Biochemical Industry Co., Ltd. will participate in CPHI Milan 2026 from October 6 to 8 at Fiera Milano, Italy. Visit Booth 1H24 to explore our pharmaceutical excipient portfolio, including Hydroxypropyl Betadex, Betadex Sulfobutyl Ether Sodium, and Beta-Cyclodextrin, together with selected APIs and pharmaceutical raw materials such as Glucosamine Sulfate Sodium Chloride, Menatetrenone, and L-Phenylalanine. Our team looks forward to meeting pharmaceutical companies, CDMOs, distributors, formulation developers, and industry partners to discuss product evaluation, technical documentation, samples, and long-term cooperation.
Cyclodextrin is a versatile excipient used across pharmaceutical, food, and nutraceutical industries. Its unique inclusion complex technology can improve drug solubility, bioavailability, stability, taste masking, and nutrient delivery, supporting advanced formulation development.
Xi’an Deli Biochemical Industry Co., Ltd. has officially announced the expansion of its active pharmaceutical ingredient (API) and excipient portfolio with the addition of Glucosamine Sulfate Sodium Chloride (CAS 1296149-13-7). Backed by over 26 years of specialized manufacturing experience, the company aims to provide high-purity ingredients, full technical documentation, and scalable global supply support for joint health formulations and pharmaceutical development. Building on its established leadership in cyclodextrin derivatives—such as Hydroxypropyl Betadex (HPBCD) and Sulfobutyl Ether Beta Cyclodextrin Sodium (SBECD)—Xi’an Deli’s latest release reinforces its strategy to deliver diversified, high-quality solutions for pharmaceutical manufacturers and partners across Europe, Asia, and global markets.
Cyclodextrins gained significant attention in pharmaceutical research after scientists such as Loftsson, Stella, and other researchers explored their unique molecular structure and solubilizing properties from 2005 to 2018. Studies conducted in universities and pharmaceutical research institutions worldwide demonstrated that cyclodextrins improve drug solubility, stability, and bioavailability, leading to their increasing application in modern drug delivery systems.
Recently, Xi'an DELI Biochemical announced new progress in the application of Betadex Sulfobutyl Ether Sodium (SBECD) at its research facility in Xi'an, China. Driven by the growing demand for effective formulation solutions for poorly soluble drugs, the company's scientists optimized inclusion complex technology to enhance drug solubility and stability. The achievement highlights the important role of SBECD in modern drug delivery systems and supports the development of high-quality pharmaceutical products worldwide.
